Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06437171 · ClinicalTrials.gov registry record · Phase 4
FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA
A Phase 4 study of Food Allergy, sponsored by AAADRS Clinical Research Center.
- Active
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06437171: Active Phase 4 study of Food Allergy, sponsored by AAADRS Clinical Research Center.
NCT06437171 is a Phase 4 study of Food Allergy that is active but no longer recruiting, run by AAADRS Clinical Research Center. The registered enrollment target is 20 participants, below the 963-participant average among 17 other Food Allergy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06437171, a Phase 4 study of Food Allergy, is active but no longer recruiting, sponsored by AAADRS Clinical Research Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.
Primary Outcome
biomarker
Conditions Studied
Interventions
- BIOLOGICAL Omalizumab
Study Locations (1)
Florida
- AAADRS Clinical Research Center - Coral Gables
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What the registry record for NCT06437171 still lists
NCT06437171 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 963-participant average among 17 other Food Allergy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Food Allergy appearing as the primary indexed condition, and to 1 intervention - of which Omalizumab is the first listed.
NCT06437171 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06437171 about?
NCT06437171 is a clinical study titled "FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA". This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.
What is the current status of trial NCT06437171?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-06-03. Estimated completion is 2026-12.
What conditions does trial NCT06437171 study?
This clinical trial studies the following conditions: Food Allergy.
What interventions are being tested in trial NCT06437171?
The interventions under investigation include: Omalizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06437171?
This trial is sponsored by AAADRS Clinical Research Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06437171 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06437171's enrollment target sits among peer trials
20 16th of 17 higher than 2 of 17 other Food Allergy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Food Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
-
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
RECRUITING
-
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
RECRUITING · Phase 1
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Natural History and Genetics of Food Allergy and Related Conditions
RECRUITING
-
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI